Health
Avacta to launch Affimer-based ELISA test for SARS-CoV-2 virus detection – News-Medical.Net
Avacta Group plc, the developer of Affimer biotherapeutics and reagents, is pleased to announce that it will launch an ELISA laboratory test for the SARS-CoV-2 spike protein to support global research efforts into the coronavirus that causes COVID-19.
Avacta Group plc, the developer of Affimer® biotherapeutics and reagents, is pleased to announce that it will launch an ELISA laboratory test for the SARS-CoV-2 spike protein to support global research efforts into the coronavirus that causes COVID-19.
Enzyme linked immunosorbent assays (“ELISAs”) are very common research tools used to detect and quantify a target of interest in a wide range of samples. Using the same Affimer reagents that are incorporated into its rapid coronavirus saliva test…
-
General9 hours agoCoroner to examine treatment of woman who died three days after surgery performed by former Queensland premier’s partner
-
General12 hours agoAlbanese beats drum on economy as trade clouds gather
-
Business8 hours agoWhy Antipa, Cettire, Magnetic Resources, and Steadfast shares are pushing higher
-
Noosa News11 hours agoSurgeon partner of former premier to testify over his patient’s death